This page was printed from the South & West Devon Formulary and Referral site at
Please ensure you are using the current version of this document
Alzheimer's disease is the commonest form of dementia. Dementia affects one in 20 people over the age of 65 and one in five over the age of 80. As definitive diagnosis is made by demonstration of pathological features in brain tissue, diagnostic criteria (e.g. ICD10, DSM IV, or NINCDS/ADRDA) have been developed to provide an assessment tool to assist diagnosis.
Acetylcholine (ACh) is a neurotransmitter that appears depleted in the brains of patients with Alzheimer's disease. Acetylcholinesterase (AChE) inhibitors elevate the levels of ACh by inhibiting an enzyme responsible for its breakdown leading to an improvement in symptoms for some patients though not altering the outcome of the disease.
NICE TA217: Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (updated June 2018)
NICE has issued the following guidance ( TA217):
The severity of Alzheimer's disease can be assessed using several methods. Severity is frequently defined by Mini Mental State Examination (MMSE) score:
Assessing the severity of Alzheimer's disease and the need for treatment should not rely solely on cognition scores in circumstances in which it would be inappropriate, for example with patients with learning disabilities or language differences.
Only specialists in the care of patients with dementia should make diagnosis of Alzheimer's disease and assess whether the individual is suitable for treatment and initiate treatment where appropriate.
The specialist should discuss with the patient and their carer(s) the benefits, side effects, frequency of dosing and monitoring requirements of their treatment.
The specialist should choose most appropriate drug, initiate treatment, prescribe and monitor the patient until the dose is stabilised. Memantine should not prescribed in combination with donepezil, rivastigmine or galantamine.
The specialist should specify any necessary monitoring and review dates at clinically relevant time intervals for both the GP and specialist team and any other patient specific information.
There should be a suitable person identified to ensure concordance with treatment (e.g. relative or other carer), either by the specialist or GP. They should also make the carer aware of the nature of the effect of treatment and that it could be stopped if the patient does not clearly benefit from the drug treatment.
Treatment should be prescribed by the GP after communication with specialists regarding the need for treatment and once the maintenance dose has been established.
For patients initially diagnosed with mild or moderate Alzheimer's disease, the patient should be referred to the specialist if a routine review of progress indicates that the severity of the patient's Alzheimer's disease has progressed to severe. A medication review by the specialist will be required.
The specialist will identify criteria to be used to assess response to treatment using the baseline assessment encompassing cognitive, global and behavioural functioning and assess activities of daily living. Again not relying solely on cognition scores in circumstances in which it would be inappropriate.
Specialist services will provide advice and, if appropriate, undertake a treatment review in response to the following situations:
Whilst the three cholinesterase inhibitors (donepezil, galantamnine and rivastigmine) are only licensed in the UK for the treatment of mild or moderate dementia, research evidence has shown that they can also have a beneficial effect in patients with a severe dementia as well. Therefore they are usually not stopped until either:
These decisions should be discussed with the family / carers and it is good practice to wean the medication off, e.g. reducing the dose by 50% for a month and then stopping. The patient then can be monitored over the next couple of weeks for signs of deterioration and the drug restated if needed, although return to previous level of functioning may not be achieved.
Please refer to SPC or current BNF for the different products for information on side-effects, cautions and contraindications
Devon Partnerships Trust
Plymouth Community Healthcare